Brokerages Expect OraSure Technologies, Inc. (OSUR) to Post $0.07 Earnings Per Share

Analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR) to post $0.07 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for OraSure Technologies’ earnings. OraSure Technologies also reported earnings of $0.07 per share during the same quarter last year. The company is expected to issue its next earnings results on Wednesday, August 2nd.

According to Zacks, analysts expect that OraSure Technologies will report full-year earnings of $0.44 per share for the current fiscal year, with EPS estimates ranging from $0.40 to $0.47. For the next financial year, analysts expect that the business will post earnings of $0.31 per share, with EPS estimates ranging from $0.30 to $0.31. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.04. OraSure Technologies had a return on equity of 11.64% and a net margin of 15.38%. The business had revenue of $32.55 million during the quarter, compared to analyst estimates of $31.19 million. During the same quarter last year, the company posted $0.04 EPS. OraSure Technologies’s revenue for the quarter was up 11.9% on a year-over-year basis.

OSUR has been the subject of several recent research reports. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, April 12th. Raymond James Financial, Inc. upgraded OraSure Technologies from a “market perform” rating to an “outperform” rating and set a $11.25 price objective on the stock in a research note on Thursday, February 9th. Jefferies Group LLC upped their price objective on OraSure Technologies from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, February 9th. Finally, Canaccord Genuity set a $12.00 target price on OraSure Technologies and gave the stock a “buy” rating in a research note on Thursday, February 9th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $12.04.

OraSure Technologies (NASDAQ:OSUR) traded up 1.18% during trading on Tuesday, hitting $14.52. The company had a trading volume of 707,494 shares. The company has a market capitalization of $838.70 million, a price-to-earnings ratio of 27.82 and a beta of 1.44. The firm has a 50-day moving average of $13.45 and a 200 day moving average of $10.55. OraSure Technologies has a 12-month low of $5.57 and a 12-month high of $15.72.

WARNING: “Brokerages Expect OraSure Technologies, Inc. (OSUR) to Post $0.07 Earnings Per Share” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/06/20/brokerages-expect-orasure-technologies-inc-osur-to-post-0-07-earnings-per-share-updated-updated-updated-updated.html.

In other OraSure Technologies news, CEO Douglas A. Michels sold 209,800 shares of OraSure Technologies stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $15.01, for a total transaction of $3,149,098.00. Following the completion of the transaction, the chief executive officer now owns 782,025 shares in the company, valued at approximately $11,738,195.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Anthony Zezzo II sold 115,000 shares of OraSure Technologies stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $14.70, for a total value of $1,690,500.00. Following the transaction, the executive vice president now owns 260,410 shares of the company’s stock, valued at approximately $3,828,027. The disclosure for this sale can be found here. Insiders have sold a total of 870,058 shares of company stock valued at $12,937,597 in the last quarter. Company insiders own 7.80% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its position in shares of OraSure Technologies by 369.4% in the first quarter. Goldman Sachs Group Inc. now owns 267,257 shares of the medical instruments supplier’s stock worth $3,455,000 after buying an additional 210,317 shares during the last quarter. Shelton Capital Management acquired a new position in shares of OraSure Technologies during the first quarter worth $336,000. Perceptive Advisors LLC acquired a new position in shares of OraSure Technologies during the first quarter worth $609,000. State Street Corp increased its position in shares of OraSure Technologies by 13.9% in the first quarter. State Street Corp now owns 1,533,294 shares of the medical instruments supplier’s stock worth $19,828,000 after buying an additional 186,775 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of OraSure Technologies by 910.8% in the first quarter. Bank of America Corp DE now owns 85,371 shares of the medical instruments supplier’s stock worth $1,104,000 after buying an additional 76,925 shares during the last quarter. Institutional investors and hedge funds own 79.51% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

12 Month Chart for NASDAQ:OSUR

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply